Nanohybrid magnetic liposome functionalized with hyaluronic acid for enhanced cellular uptake and near-infrared-triggered drug release

Nguyen, Van Du; Zheng, Shaohui; Han, Jiwon; Le, Viet Ha; Park, Jong-Oh; Park, Sukho

doi:10.1016/j.colsurfb.2017.03.008

Cited by 62 publications

(32 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies utilizing liposomal-based NPs for PCa and BC theranostic techniques are few [238,239,240,241,242,243,244,245,246,247], although applications for therapy or imaging alone are significantly more frequently published [248,249,250,251,252,253,254,255,256,257,258,259,260,261]. For example, Yeh et al recently published results from experiments investigating peptide-conjugated liposomal NPs in a theranostic approach for PCa.…”

Section: Nanoparticles For Prostate and Breast Cancermentioning

confidence: 99%

“…However, a large number of studies, using different techniques, have been published with a NP and CTH-based approach for both PCa and BC, of which only a tiny fraction are listed here [105,253,315,353,422,423,424,425,426,427,428,429,430,431]. For example, Belz et al recently designed ultra-small silica NPs containing the radiosensitizing drug docetaxel for combined chemoradiation therapy, with potential benefit for patients with PCa [425].…”

Section: Multimodal Therapy Options For Prostate and Breast Cancermentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Elgqvist

2017

IJMS

View full text Add to dashboard Cite

Prostate and breast cancer are the second most and most commonly diagnosed cancer in men and women worldwide, respectively. The American Cancer Society estimates that during 2016 in the USA around 430,000 individuals were diagnosed with one of these two types of cancers, and approximately 15% of them will die from the disease. In Europe, the rate of incidences and deaths are similar to those in the USA. Several different more or less successful diagnostic and therapeutic approaches have been developed and evaluated in order to tackle this issue and thereby decrease the death rates. By using nanoparticles as vehicles carrying both diagnostic and therapeutic molecular entities, individualized targeted theranostic nanomedicine has emerged as a promising option to increase the sensitivity and the specificity during diagnosis, as well as the likelihood of survival or prolonged survival after therapy. This article presents and discusses important and promising different kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications. The presentation of different nanoparticles and theranostic applications is quite general, but there is a special focus on prostate cancer. Some references and aspects regarding breast cancer are however also presented and discussed. Finally, the prostate cancer case is presented in more detail regarding diagnosis, staging, recurrence, metastases, and treatment options available today, followed by possible ways to move forward applying theranostics for both prostate and breast cancer based on promising experiments performed until today.

show abstract

Section: Nanoparticles For Prostate and Breast Cancermentioning

confidence: 99%

Section: Multimodal Therapy Options For Prostate and Breast Cancermentioning

confidence: 99%

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Elgqvist

2017

IJMS

View full text Add to dashboard Cite

show abstract

“…HA can be also conjugated to phospholipids in order to develop surface-modified liposomes: the chemical modification can be performed prior to liposome formulation [184] or after, on the outside shell [185,186]. Moreover, HA can be also non-covalently linked on liposome surface: indeed, liposomes can be covered by HA through ionic interaction mechanism [187,188] or simple lipid film hydration technique [189].…”

Section: Drug Delivery Systemsmentioning

confidence: 99%

“…HA-modified liposomes appear promising carriers, as they have been shown to enhance the stability of drugs in the bloodstream, prolong their half-life time, reduce their systemic toxicity [186], enhance their tissue permeability, sustain their prolonged release [189] and ameliorate their therapeutic effects through synergistic actions [190]. HA-coated liposomes could improve the safety and the efficacy of antitumoral therapies: they appear proficient in mediating site-specific delivery of siRNA [191] and anticancer drugs such as doxorubicin [185], gemcitabine [186], imatinib mesylate [188] and docetaxel [184], via CD44 cell receptors. Additionally, HA-surface-modified liposomes have been investigated as delivery systems also in ophthalmology [189], pneumology [190] and topical treatment of wounds and burns [40].…”

Section: Drug Delivery Systemsmentioning

confidence: 99%

“…Many researches have shown that HA can act as drug carrier and targeting agent at the same time, under the form of polymer-antitumoral conjugates, or delivery systems encapsulating anticancer drugs [179]. Additionally, hyaluronan can be employed to design surface-modified nanoparticles [196][197][198] or liposomes [184][185][186][187][188]. After CD44 receptor-mediated cell internalization, all these HA derivatives are hydrolyzed by intracellular enzymes and, therefore, drugs are released inside the cancer target cells [179].…”

Section: Cancer Therapymentioning

confidence: 99%

See 1 more Smart Citation

Hyaluronic Acid in the 3<sup>rd</sup> Millennium

Fallacara¹,

Baldini²,

Manfredini³

et al. 2018

Preprint

View full text Add to dashboard Cite

Since its first isolation in 1934, hyaluronic acid (HA) has been studied across a variety of research areas. This unbranched glycosaminoglycan consisting of repeating disaccharide units of N-acetyl-D-glucosamine and D-glucuronic acid is almost ubiquitary in humans and in other vertebrates. HA is involved in many key processes -including cell signaling, wound reparation, tissue regeneration, morphogenesis, matrix organization and pathobiology-, and has unique physico-chemical properties -such as biocompatibility, biodegradability, mucoadhesivity, hygroscopicity and viscoelasticity. For these reasons, exogenous HA has been investigated as drug delivery system and treatment in cancer, ophthalmology, arthrology, pneumology, rhinology, urology, aesthetic medicine and cosmetic. To improve and customize its properties and applications, HA can be subjected to chemical modifications: conjugation and crosslinking. The present review gives an overview regarding HA, describing its history, physico-chemical, structural and hydrodynamic properties, and biology -occurrence, biosynthesis (by hyaluronan synthases), degradation (by hyaluronidases and oxidative stress), roles, mechanisms of action and receptors. Furthermore, both conventional and recently emerging methods developed for the industrial production of HA and its chemical derivatization are presented. Finally, the medical, pharmaceutical and cosmetic applications of HA and its derivatives are reviewed, reporting examples of HA-based products which currently are on the market or are undergoing further investigations.

show abstract